Ken Griffin
RXRX icon

Ken Griffin’s Recursion Pharmaceuticals RXRX Stock Holding History

Ken Griffin’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.92M Sell
624,659
-3,605,340
-85% -$13.9M ﹤0.01% 6142
2025
Q4 		$17.3M Buy
4,229,999
+2,881,315
+214% +$14.3M ﹤0.01% 2529
2025
Q3 		$6.58M Buy
1,348,684
+34,132
+3% +$179K ﹤0.01% 3883
2025
Q2 		$6.65M Sell
1,314,552
-1,341,159
-51% -$6.59M ﹤0.01% 3636
2025
Q1 		$14M Sell
2,655,711
-83,536
-3% -$609K ﹤0.01% 2438
2024
Q4 		$18.5M Buy
2,739,247
+2,505,024
+1,070% +$16.8M ﹤0.01% 2238
2024
Q3 		$1.54M Sell
234,223
-510,856
-69% -$3.66M ﹤0.01% 6000
2024
Q2 		$5.59M Buy
745,079
+404,705
+119% +$3.53M ﹤0.01% 3578
2024
Q1 		$3.39M Buy
340,374
+303,880
+833% +$3.38M ﹤0.01% 4577
2023
Q4 		$360K Sell
36,494
-266,596
-88% -$1.9M ﹤0.01% 8781
2023
Q3 		$2.32M Sell
303,090
-434,668
-59% -$4.34M ﹤0.01% 4954
2023
Q2 		$5.51M Buy
737,758
+132,243
+22% +$925K ﹤0.01% 3503
2023
Q1 		$4.04M Sell
605,515
-165,635
-21% -$1.31M ﹤0.01% 4144
2022
Q4 		$5.95M Buy
771,150
+269,280
+54% +$2.64M ﹤0.01% 3579
2022
Q3 		$5.34M Buy
501,870
+194,498
+63% +$1.97M ﹤0.01% 3755
2022
Q2 		$2.5M Sell
307,372
-602,598
-66% -$4.03M ﹤0.01% 5104
2022
Q1 		$6.51M Buy
909,970
+710,363
+356% +$7.55M ﹤0.01% 3671
2021
Q4 		$3.42M Buy
+199,607
New +$3.76M ﹤0.01% 5085

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ken Griffin's RXRX Position: Q1 2026 in Review

Ken Griffin reduced its Recursion Pharmaceuticals (RXRX) stake by 85% in Q1 2026, selling an estimated $13.9M and leaving 624,659 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #6142.

Ken Griffin first reported a position in RXRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $18.5M in Q4 2024. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Ken Griffin held 624,659 shares of Recursion Pharmaceuticals worth $1.92M as of Q1 2026.
  • Ken Griffin sold 3,605,340 Recursion Pharmaceuticals shares in Q1 2026, an estimated $13.9M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #6142 holding.
  • Ken Griffin first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Ken Griffin's Recursion Pharmaceuticals position peaked at $18.5M in Q4 2024.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.